期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 11, 期 9, 页码 1047-1055出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2013.0127
关键词
-
类别
资金
- Eisai, Inc.
- Millennium: The Takeda Oncology Company
- Teva Pharmaceuticals
- Bayer HealthCare Pharmaceuticals Inc.
- Celgene Corporation
- Endo Pharmaceuticals and HealthTronics
- Genentech
- ARIAD Pharmaceuticals, Inc.
These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocytic leukemia (APL) section, featuring recommendations for additional induction/consolidation regimens in patients with low- or intermediate-risk APL, and providing guidance on maintenance strategies for APL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据